DexCom (NASDAQ:DXCM) Director Sells $170,640.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 2,000 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

NASDAQ DXCM opened at $83.02 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The company has a market cap of $31.33 billion, a P/E ratio of 32.81, a P/E/G ratio of 1.38 and a beta of 1.41. The stock has a 50-day moving average of $74.20 and a two-hundred day moving average of $69.62. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $87.85.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.48 earnings per share. As a group, analysts anticipate that DexCom, Inc. will post 2.65 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Brighton Jones LLC increased its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC boosted its position in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC grew its stake in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the last quarter. Focus Partners Wealth grew its stake in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC increased its position in DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after buying an additional 258 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research note on Friday, May 1st. Truist Financial set a $93.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Robert W. Baird set a $105.00 target price on DexCom in a report on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the stock a “buy” rating in a research note on Monday. Finally, Bank of America cut their price target on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.